Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Hejazi M, Manser AR, Fröbel J, Kündgen A, Zhao X, Schönberg K, Germing U, Haas R, Gattermann N, Uhrberg M.

Haematologica. 2015 Feb 14. pii: haematol.2014.118679. [Epub ahead of print]

2.

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.

Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, Nachtkamp K, Neukirchen J, Strupp C, Aul C, Haas R, Gattermann N, Germing U.

Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12512. [Epub ahead of print]

PMID:
25600827
3.

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, Hildebrandt B, Haas R, Gattermann N, Germing U.

Leuk Res. 2014 Dec;38(12):1413-9. doi: 10.1016/j.leukres.2014.09.003. Epub 2014 Sep 17.

PMID:
25444076
4.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF.

Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. Review.

5.

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.

Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C.

Genome Med. 2014 Apr 30;6(4):34. doi: 10.1186/gm551. eCollection 2014.

6.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

Steensma DP, Gattermann N.

Best Pract Res Clin Haematol. 2013 Dec;26(4):431-44. doi: 10.1016/j.beha.2013.09.009. Epub 2013 Oct 1. Review. Erratum in: Best Pract Res Clin Haematol. 2014 Jun;27(2):e1.

PMID:
24507819
7.

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U.

Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24. No abstract available.

8.

Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Germing U, Kobbe G, Haas R, Gattermann N.

Dtsch Arztebl Int. 2013 Nov 15;110(46):783-90. doi: 10.3238/arztebl.2013.0783. Review.

9.

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.

Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. No abstract available.

PMID:
24186004
10.

The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.

Gattermann N, Kündgen A, Kellermann L, Zeffel M, Paessens B, Germing U.

Eur J Haematol. 2013 Dec;91(6):473-82. doi: 10.1111/ejh.12196. Epub 2013 Sep 18.

PMID:
24102637
11.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net.

Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.

12.

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.

Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, Gattermann N, Germing U.

Ann Hematol. 2013 Dec;92(12):1617-23. doi: 10.1007/s00277-013-1839-5. Epub 2013 Jul 11.

PMID:
23842708
13.

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T.

Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29.

PMID:
23797473
14.

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM.

Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6.

15.

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31.

PMID:
23122806
16.

SF3B1 and the riddle of the ring sideroblast.

Gattermann N.

Blood. 2012 Oct 18;120(16):3167-8. doi: 10.1182/blood-2012-08-447094. No abstract available.

17.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
18.

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Viprakasit V, Gattermann N, Lee JW, Porter JB, Taher AT, Habr D, Martin N, Domokos G, Cappellini MD.

Blood Transfus. 2013 Jan;11(1):108-22. doi: 10.2450/2012.0012-12. Epub 2012 Jul 12.

19.
20.

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM.

Leukemia. 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. Epub 2012 Jul 5.

PMID:
22763385
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk